A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement
用于经导管主动脉瓣置换的新型聚合物瓣膜
基本信息
- 批准号:10221033
- 负责人:
- 金额:$ 67.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse eventAnimalsAortic Valve StenosisBenchmarkingBiological AssayBiological MarkersBioprosthesis deviceBlood PlateletsBlood VesselsBusinessesCardiacCardiovascular systemCathetersChronicClinicalClinical ResearchClinical TrialsCollaborationsComplicationCorrosionCoupledCyclic GMPDepositionDeteriorationDevelopmentDevicesDimensionsDistalEmbolismEuthanasiaEventExtravasationFailureFollow-Up StudiesFreezingFutureGenerationsGeometryGoalsGrantGuidelinesHeartHeart ValvesHemolysisHistologicImplantIn SituIn VitroInstitutionLeftLifeLife Cycle StagesLongterm Follow-upManufacturer NameMeasuresMedical DeviceMethodologyMicroscopicMoldsMolecular ConformationMonitorNational Institute of Biomedical Imaging and BioengineeringOperative Surgical ProceduresOrganOutcomePathologyPatientsPerformancePhasePlant RootsPolymersPopulationPrincipal InvestigatorProceduresProcessProsthesisRadialRegulationResistanceRiskRisk FactorsSafetySavingsSerious Adverse EventSheepSmall Business Technology Transfer ResearchStandardizationStentsStressStrokeSurfaceSurgical ValvesSystemTechnologyTestingTherapeutic EmbolizationThickThrombosisTissuesTranslatingUnited States National Institutes of HealthUniversitiesVentricularWorkX-Ray Computed Tomographyaortic valveaortic valve disorderaortic valve replacementbasebiomaterial compatibilitybonecalcificationcommercializationcrosslinkcytotoxicitydesigneffective therapyefficacy testingexperimental studyfirst-in-humangenotoxicityheart imaginghemocompatibilityhemodynamicshigh riskimprovedin vitro testingin vivoin vivo evaluationinnovationmanufacturing processmechanical propertiesmeetingsmigrationminimally invasivenew technologynovelolder patientoxidationpatient populationperformance testspre-clinicalpressureprogramsprototypequantumreplicatorresearch and developmentsheep modelsimulationsuccessthrombogenesisthromboticvalve replacementverification and validation
项目摘要
Project Summary: A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement
Minimally invasive transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for the unmet
clinical need of inoperable patients with severe aortic stenosis (AS). Recent longitudinal follow-up studies of TAVR
patients however indicate that this procedure and associated technology may result in serious adverse events. Current
technology is based on tissue valves adapted to, but not specifically designed for TAVR. Those may sustain damage
during crimping as well as deployment, are susceptible to ‘bone-like’ calcific deposition, and suffer from limited
durability. In a collaboration between Stony Brook University and PolyNova Cardiovascular, Inc., we have developed
a novel valve that is specifically designed to tackle the numerous challenges that a TAVR valve will meet during its
life cycle, from crimping to deployment and long term performance in situ. It incorporates (i) novel polymer technology,
xSIBS, which combines superior bio-stability together with excellent mechanical properties, and (ii) a novel design
optimization methodology of the leaflets profile for enhanced hemodynamics, durability, and thromboresistance
performance.
Our broad objective is to develop a viable and durable TAVR valve that will propose a real alternative to existing
bioprosthetic aortic valves, and allow a long-term solution adequate for broader segment of the population. Following
a successful Phase I STTR project, in this Phase II project we aim to expand the R&D activities of our polymeric valve
toward First-In-Man, and implement a robust regulatory and quality management system plans.
The proposed project includes 4 Aims: Aim 1 expand our set of advanced computational flow simulations,
development of a 2nd generation valve, development of a dedicated delivery catheter system, and expanding our valve
product to a complete set of valve sizes. Aim 2 tests the valve performance according to the ISO 5840-3 (transcatheter
heart valves), ISO 25539-1 (cardiovascular implants), and ISO10993-1 (biocompatibility). We will also modify our
valve manufacturing capabilities to be compliant with the FDA quality management system. Aim 3 tests the valves in
vivo in sheep model. The valves are tested for efficacy and safety in acute tests as well as chronic 10 and 20 wks.
Aim 4 is dedicated for integrating regulatory and business plans for PolyNova and for the valve technology.
Integral to this STTR Phase II project is a detailed commercialization and regulatory plan, based on which, and under
the support of this Phase II program, we will convert PolyNova from a pure R&D shop to firm establishment as a
qualified medical device manufacturer– i.e. institution of a fully cGMP, FDA compliant Quality Management System
including a robust Design Control process.
Successful accomplishment of the above aims will lead to a breakthrough in the treatment of aortic valve diseases,
providing an affordable, long-term, minimally invasive solution, enhancing the life of a much broader patient
population.
项目摘要:用于经导管主动脉瓣置换术的新型聚合物瓣膜
微创经导管主动脉瓣置换术 (TAVR) 已成为治疗未满足治疗需求的有效疗法
无法手术的严重主动脉瓣狭窄(AS)患者的临床需求。最近 TAVR 的纵向随访研究
然而,患者表示该手术和相关技术可能会导致严重的不良事件。当前的
技术基于适应 TAVR 的组织瓣膜,但并非专门为 TAVR 设计。这些可能会受到损害
在压接和展开过程中,容易发生“骨状”钙化沉积,并且受到有限的影响
耐用性。在石溪大学和 PolyNova Cardioangio, Inc. 的合作中,我们开发了
一种新型阀门,专为解决 TAVR 瓣膜在使用过程中遇到的众多挑战而设计
生命周期,从压接到部署以及现场长期性能。它结合了(i)新颖的聚合物技术,
xSIBS,结合了卓越的生物稳定性和优异的机械性能,以及 (ii) 新颖的设计
用于增强血流动力学、耐用性和抗血栓性的传单轮廓的优化方法
表现。
我们的总体目标是开发一种可行且耐用的 TAVR 瓣膜,为现有的 TAVR 瓣膜提供真正的替代品
生物主动脉瓣膜,并提供适合更广泛人群的长期解决方案。下列的
作为一个成功的第一阶段 STTR 项目,在这个第二阶段项目中,我们的目标是扩大我们的聚合物阀门的研发活动
迈向“First-In-Man”,并实施强有力的监管和质量管理体系计划。
拟议项目包括 4 个目标:目标 1 扩展我们的高级计算流模拟集,
开发第二代瓣膜、开发专用输送导管系统并扩展我们的瓣膜
产品到一整套阀门尺寸。目标 2 根据 ISO 5840-3(经导管
心脏瓣膜)、ISO 25539-1(心血管植入物)和 ISO10993-1(生物相容性)。我们还将修改我们的
阀门制造能力符合 FDA 质量管理体系。目标 3 测试阀门
绵羊模型体内。这些阀门在急性测试以及 10 周和 20 周的慢性测试中进行了有效性和安全性测试。
Aim 4 致力于整合 PolyNova 和阀门技术的监管和业务计划。
STTR 第二阶段项目的组成部分是详细的商业化和监管计划,并在此基础上制定
在这个二期项目的支持下,我们将把PolyNova从一个纯粹的研发机构转变为一家公司
合格的医疗器械制造商——即建立完全符合 cGMP、FDA 要求的质量管理体系
包括强大的设计控制流程。
上述目标的成功实现将为主动脉瓣疾病的治疗带来突破,
提供负担得起的、长期的、微创的解决方案,改善更广泛患者的生活
人口。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANNY BLUESTEIN其他文献
DANNY BLUESTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANNY BLUESTEIN', 18)}}的其他基金
Biomechanical Approaches and Technologies for Enhancing TAVR Outcomes
提高 TAVR 效果的生物力学方法和技术
- 批准号:
10201598 - 财政年份:2018
- 资助金额:
$ 67.56万 - 项目类别:
Biomechanical Approaches and Technologies for Enhancing TAVR Outcomes
提高 TAVR 效果的生物力学方法和技术
- 批准号:
10449331 - 财政年份:2018
- 资助金额:
$ 67.56万 - 项目类别:
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement
用于经导管主动脉瓣置换的新型聚合物瓣膜
- 批准号:
9344868 - 财政年份:2017
- 资助金额:
$ 67.56万 - 项目类别:
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement
用于经导管主动脉瓣置换的新型聚合物瓣膜
- 批准号:
9903032 - 财政年份:2017
- 资助金额:
$ 67.56万 - 项目类别:
A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement
用于经导管主动脉瓣置换的新型聚合物瓣膜
- 批准号:
10464978 - 财政年份:2017
- 资助金额:
$ 67.56万 - 项目类别:
Multiscale Modeling of Blood Flow and Platelet Mediated Thrombosis
血流和血小板介导的血栓形成的多尺度建模
- 批准号:
9032130 - 财政年份:2016
- 资助金额:
$ 67.56万 - 项目类别:
Multiscale Modeling of Blood Flow and Platelet Mediated Thrombosis
血流和血小板介导的血栓形成的多尺度建模
- 批准号:
9265504 - 财政年份:2016
- 资助金额:
$ 67.56万 - 项目类别:
Multiscale modeling of blood flow and clotting in cardiovascular devices
心血管设备中血流和凝血的多尺度建模
- 批准号:
8114454 - 财政年份:2011
- 资助金额:
$ 67.56万 - 项目类别:
Multiscale modeling of blood flow and clotting in cardiovascular devices
心血管设备中血流和凝血的多尺度建模
- 批准号:
8258220 - 财政年份:2011
- 资助金额:
$ 67.56万 - 项目类别:
Optimizing Cardiovascular Device Thromboresistance for Eliminating Anticoagulants
优化心血管装置的抗血栓能力以消除抗凝剂
- 批准号:
8016863 - 财政年份:2010
- 资助金额:
$ 67.56万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 67.56万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 67.56万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 67.56万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 67.56万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 67.56万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 67.56万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 67.56万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 67.56万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 67.56万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 67.56万 - 项目类别: